Novartis

News

Novartis gets FDA OK for first in its trio of IgAN therapies

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug.

News

Novartis, Viatris latest targets of Henrietta Lacks lawsuits

Novartis and Viatris have become the latest pharma companies to be named in lawsuits claiming that they profited from the unlawful use of HeLa cells derived from cells taken from a cancer p

News

Four drugmakers found to have breached ABPI code

Novartis, Pfizer, Otsuka and Novo Nordisk have been called out by the UK’s Prescription Medicines Code of Practice Authority (PMCPA) for breaching the Association of the British Pharmaceuti

News

Italy starts probe into Lucentis biosimilar delay allegation

Italy’s antitrust authority has launched an investigation against eight pharma companies, including Novartis and Roche, over suspicion they may have colluded to delay the

News

ASCO: Novartis’ Scemblix aces first-line CML study

Novartis’ first-in-class STAMP inhibitor Scemblix could be headed for use earlier in the treatment pathway for chronic myeloid leukaemia (CML).

News

Novartis cues up filings for remibrutinib in chronic hives

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – a

Novartis gets FDA OK for first in its trio of IgAN therapies

Novartis, Viatris latest targets of Henrietta Lacks lawsuits

Four drugmakers found to have breached ABPI code

Italy starts probe into Lucentis biosimilar delay allegation

ASCO: Novartis’ Scemblix aces first-line CML study

Novartis cues up filings for remibrutinib in chronic hives

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Novartis

Editor's Picks